JP2014527061A5 - - Google Patents

Download PDF

Info

Publication number
JP2014527061A5
JP2014527061A5 JP2014527322A JP2014527322A JP2014527061A5 JP 2014527061 A5 JP2014527061 A5 JP 2014527061A5 JP 2014527322 A JP2014527322 A JP 2014527322A JP 2014527322 A JP2014527322 A JP 2014527322A JP 2014527061 A5 JP2014527061 A5 JP 2014527061A5
Authority
JP
Japan
Prior art keywords
methyl
imidazol
carbonyl
hcv
biphenylyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014527322A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014527061A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/052216 external-priority patent/WO2013028953A1/en
Publication of JP2014527061A publication Critical patent/JP2014527061A/ja
Publication of JP2014527061A5 publication Critical patent/JP2014527061A5/ja
Pending legal-status Critical Current

Links

JP2014527322A 2011-08-24 2012-08-24 C型肝炎の組合せ治療 Pending JP2014527061A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161526798P 2011-08-24 2011-08-24
US61/526,798 2011-08-24
US201161529358P 2011-08-31 2011-08-31
US61/529,358 2011-08-31
US201261617813P 2012-03-30 2012-03-30
US61/617,813 2012-03-30
PCT/US2012/052216 WO2013028953A1 (en) 2011-08-24 2012-08-24 Combination treatments for hepatitis c

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017083252A Division JP2017165746A (ja) 2011-08-24 2017-04-20 C型肝炎の組合せ治療

Publications (2)

Publication Number Publication Date
JP2014527061A JP2014527061A (ja) 2014-10-09
JP2014527061A5 true JP2014527061A5 (enExample) 2015-10-08

Family

ID=47746891

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014527322A Pending JP2014527061A (ja) 2011-08-24 2012-08-24 C型肝炎の組合せ治療
JP2017083252A Pending JP2017165746A (ja) 2011-08-24 2017-04-20 C型肝炎の組合せ治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017083252A Pending JP2017165746A (ja) 2011-08-24 2017-04-20 C型肝炎の組合せ治療

Country Status (18)

Country Link
US (1) US20140234253A1 (enExample)
EP (1) EP2747569A4 (enExample)
JP (2) JP2014527061A (enExample)
KR (1) KR20140065427A (enExample)
CN (1) CN103917095A (enExample)
AU (1) AU2012298750A1 (enExample)
BR (1) BR112014004182A2 (enExample)
CA (1) CA2845321A1 (enExample)
CL (1) CL2014000428A1 (enExample)
CO (1) CO6890100A2 (enExample)
CR (1) CR20140086A (enExample)
EA (1) EA201490254A1 (enExample)
HK (1) HK1198869A1 (enExample)
IL (1) IL230844A0 (enExample)
MX (1) MX2014002171A (enExample)
PH (1) PH12014500386A1 (enExample)
SG (1) SG2014010490A (enExample)
WO (1) WO2013028953A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120993A1 (es) * 2009-09-04 2012-08-22 Janssen Pharmaceuticals Inc Derivados bifenilicos como antivirales
KR101975233B1 (ko) 2011-08-17 2019-05-07 글락소스미스클라인 엘엘씨 치료 방법
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
PT107894A (pt) 2011-10-21 2014-10-31 Abbvie Inc Métodos para o tratamento de hcv compreendendo pelo menos dois agentes antivirais de actuação directa, ribavirina, mas não interferão.
GB2515942A (en) 2011-10-21 2015-01-07 Abbvie Inc Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN105705511A (zh) 2013-04-12 2016-06-22 艾其林医药公司 用于治疗hcv的氘化核苷前药
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
EP3019196B1 (en) * 2013-07-09 2018-06-06 Bristol-Myers Squibb Company Combinations of hepatitis c virus inhibitors
WO2015009744A1 (en) 2013-07-17 2015-01-22 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of hcv
CN104725365B (zh) * 2013-12-23 2019-02-26 南京圣和药业股份有限公司 丙型肝炎病毒抑制剂及其应用
CA2935089C (en) * 2013-12-31 2018-11-27 Nanjing Sanhome Pharmaceutical Co., Ltd. 9,9,10,10-tetrafluoro-9,10-dihydrophenanthrene hepatitis c virus inhibitor and application thereof
CN106279121B (zh) * 2014-01-21 2019-05-24 杭州普晒医药科技有限公司 一种化合物的盐及晶型或无定型物、其制备方法、含有它们的药物组合物和用途
SG11201703645XA (en) * 2014-11-10 2017-06-29 Glaxosmithkline Intellectual Property (No 2) Ltd Long acting pharmaceutical compositions for hepatitis c
MA41812A (fr) * 2015-03-27 2018-01-30 Janssen Pharmaceuticals Inc Procédés et intermédiaires pour la préparation d'un inhibiteur de protéase macrocyclique du vhc
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CN110693887B (zh) * 2019-05-17 2022-06-17 歌礼药业(浙江)有限公司 包含索磷布韦和拉维达韦的片剂及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100158862A1 (en) * 2006-08-11 2010-06-24 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8303944B2 (en) * 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7704992B2 (en) * 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ES2435799T3 (es) * 2008-10-09 2013-12-23 Anadys Pharmaceuticals, Inc. Un método de inhibición del virus de la hepatitis C mediante combinación de una 5,6-dihidro-1H-piridin-2-ona y de uno o más compuestos antivirales adicionales
WO2010062821A1 (en) * 2008-11-28 2010-06-03 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
MX2011007195A (es) * 2009-01-07 2013-07-12 Scynexis Inc Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
MX363732B (es) * 2009-05-13 2019-04-01 Gilead Pharmasset Llc Star Compuestos antivirales.
PE20120993A1 (es) * 2009-09-04 2012-08-22 Janssen Pharmaceuticals Inc Derivados bifenilicos como antivirales
US8415374B2 (en) * 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
US8377980B2 (en) * 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2784748A1 (en) * 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
WO2012040126A1 (en) * 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs

Similar Documents

Publication Publication Date Title
JP2014527061A5 (enExample)
AU2014239563B2 (en) Combination of two antivirals for treating hepatitis C
US8415374B2 (en) Combinations of hepatitis C virus inhibitors
US20130072528A1 (en) Methods for Treating HCV
ES2654109T3 (es) Combinación de agentes antivirales de acción directa y ribavirina para tratar pacientes con el VHC
CA2942823C (en) Methods for treating hcv
JP2017165746A (ja) C型肝炎の組合せ治療
EP2773342A1 (en) Compositions useful for the treatment of viral diseases
US20150011481A1 (en) Methods for Treating HCV
US20130172240A1 (en) Methods for treating hcv
AU2015240753B2 (en) Methods for treating HCV
CN104379145A (zh) Abt-450和利托那韦和例如abt-072和/或abt-333用于在治疗hcv中使用的联合治疗
US20170360783A1 (en) Methods for Treating HCV
US20170151238A1 (en) Methods for Treating HCV
US20200330460A1 (en) Methods for Treating HCV
EP3437643A1 (en) Methods for treating hcv
EP3360555A1 (en) Methods for treating hcv
HK40004326A (en) Methods for treating hcv
WO2016134058A1 (en) Combinations useful to treat hepatitis c virus